AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

TGTX · NASDAQ · Biotechnology

TG Therapeutics (TGTX)

Commercializes BRIUMVI while developing B-cell therapies for immune-mediated diseases.

$54.89

vs last close−3.22 (−5.54%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	166	44	63	73	84	108	121	141	162	193	205	240
Cost of revenue	4	8	6	8	9	15	16	19	28	38	34	41
Gross profit	162	36	58	65	75	93	105	122	134	154	171	199
	48	49	67	56	62	63	97	87	104	104	137	177
Research & development	15	17	33	18	20	24	46	32	41	41	48	95
	33	31	34	39	42	39	50	56	63	63	88	82
Selling & marketing	0	−3	0	0	0	0	0	0	0	0	0	0
General & administrative	33	34	35	39	42	39	50	56	63	63	88	82
Other expenses	0	0	0	0	0	0	0	0	0	0	0	0
Operating income	115	−12	−9	9	12	30	9	35	29	50	35	22
	−1	−2	−1	−2	−8	−4	−3	−4	−3	−5	−14	−11
Interest expense	4	2	2	4	11	7	7	7	7	7	8	17
Other non-operating income	−3	−1	−1	−2	−3	−3	−4	−3	−3	−1	7	0
Income before tax	114	−14	−11	7	4	25	5	31	26	45	20	10
Income tax expense	0	0	0	0	0	2	0	3	−365	22	1	2
Net income from continuing operations	114	−14	−11	7	4	23	5	28	391	23	20	8
Net income	114	−14	−11	7	4	23	5	28	391	23	20	8
EPS, basic	$0.80	−$0.10	−$0.07	$0.05	$0.03	$0.16	$0.03	$0.19	$2.69	$0.16	$0.14	$0.05
EPS, diluted	$0.73	−$0.10	−$0.07	$0.04	$0.02	$0.15	$0.03	$0.17	$2.43	$0.14	$0.12	$0.05
Weighted average shares, basic	143	143	146	145	145	145	147	147	145	143	144	142
Weighted average shares, diluted	156	143	146	159	161	160	163	163	161	159	160	157
EBITDA	118	−12	−8	11	15	33	12	38	33	52	28	22
Depreciation & amortization	0	0	0	0	0	0	0	0	0	0	0	0
EBIT	118	−12	−8	11	15	33	12	38	33	52	28	22